scholarly journals Vasopressor-Induced Digital Ischemia

Cureus ◽  
2021 ◽  
Author(s):  
Shruti Jesani ◽  
Sherif Elkattawy ◽  
Muhammad Atif Masood Noori ◽  
Sarah Ayad ◽  
Suha Abuaita ◽  
...  
Keyword(s):  
Digital Ischemia

scholarly journals AB0440 CLINICAL AND IMMUNOLOGICAL FEATURES OF THE SYSTEMIC SCLEROSIS-OVERLAP SYNDROMES

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1248.2-1248
Author(s):  
O. Desinova ◽  
M. Starovoytova ◽  
L. P. Ananyeva ◽  
O. Koneva ◽  
L. Garzanova ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pathological Process ◽  
Point Of View ◽  
Joint Involvement ◽  
Laboratory Findings ◽  
Overlap Syndromes ◽  
Digital Ischemia ◽  
Immune Alterations ◽  
Clinical Variants

Background:Systemic Sclerosis (SSc) overlap syndromes (SSc with polymyositis / dermatomyositis (PM/DM), rheumatoid arthritis (RA), etc.) still remain a group of very heterogenous and not very well studied clinical variants of SSc that are characterized by certain clinical and immunological features.Objectives:Identify clinical and immunological features of the SSc-overlap syndromesMethods:80 pts with SSc-PM/DM and 35 pts with SSc-RA undergoing standard clinical examination and laboratory immunological evaluation.Results:ANA Hep2 was positive in 98% of SSc-PM/DM pts; a-Scl-70 was in 34%, a - PM-Scl and RF were in 20%. ACA (6%), a-RNP (9%), and a - Jo-1 (5%) were significantly less common. Correlation analysis showed significant prevalence of conduction abnormalities in pts with a-Scl-70- (p<0.03); PM-Scl was rarely associated with cardiac arrhythmia (p<0.02) and pericarditis (p<0.03), but there was an association between ACA and presence of digital ischemia (p<0.04). Three pts with limited skin had Scl-70 and PM-Scl antibodies, two of them manifested clinical features of DM. A-Jo-1 was found in 3 pts with a longstanding disease (14,10 and 7 years), and one of these pts was also positive for a-Scl-70. All pts had limited skin and two had interstitial lung disease with FVC values of 79% and 74.8%.ANA Hep2 was positive in 96% of SSc-RA pts; a-Scl-70 – in 28%, and a-RNP - in 30%. RF-positivity was in 72% of pts, and Anti-CCP - in 27%. Simultaneous Anti-CCP and a-Scl-70 was found in one case, and Anti-CCP - anti-RNP – in another, both were associated with low RF titers. All pts had early joint involvement which became prevailing in subsequent years, and onset of the disease between 30 and 36 years. There was a correlation between laboratory signs of inflammatory activity and immunological disorders: ESR and a-Scl-70 (p<0.03). Anti-CCP and a-Scl-70 co-positivity was a significantly less frequent phenomenon (p<0.04). There was a remarkable 28% proportion of a-Scl-70 cases in SSc-RA with limited cutaneous which is usually characterized by ACA-positivity.Conclusion:SSc-PM/DM and SSc-RA appear to be an active disease from the immunological point of view, confirming therefore an important role of immune alterations in disease progression. Laboratory findings display specific pathogenetic features of SSc-overlap syndromes; laboratory abnormalities can be used to measure the activity and specify characteristics of the pathological process.Disclosure of Interests:None declared

scholarly journals Non-target digital ischemia in an ulnar artery distribution following transradial access: Case report and review of best practice techniques

2021 ◽  
pp. 112972982110008
Author(s):  
Patrick Kennedy ◽  
Darren Klass ◽  
John Chung
Keyword(s):  
Best Practice ◽  
Artery Aneurysm ◽  
Ulnar Artery ◽  
Complication Rates ◽  
Endovascular Interventions ◽  
Transradial Access ◽  
Digital Ischemia ◽  
Aneurysm Embolization ◽  
Lower Complication ◽  
Access Complications

Transradial access is a safe approach for visceral endovascular interventions, with lower complication rates compared to transfemoral access. This report describes an unusual case of ulnar artery thrombosis following splenic artery aneurysm embolization via left transradial approach, resulting in non-target digital ischemia and eventual amputation of the ring and little finger distal phalanges. Technical considerations to reduce the incidence of access complications are also reviewed, along with practice modifications undertaken at our institution following this case to improve outcomes.

Fibromuscular Dysplasia of Distal Radial and Ulnar Arteries: Uncommon Cause of Digital Ischemia

1994 ◽  
Vol 33 (6) ◽  
pp. 652-655 ◽  
Author(s):  
Vijay P. Khatri ◽  
J Claude Gaulin ◽  
Atul K. Amin
Keyword(s):  
Fibromuscular Dysplasia ◽  
Digital Ischemia

scholarly journals Digital Ischemia in Patients with Solid Tumors: a Case Report and Review of the Literature

2011 ◽  
Vol 02 (02) ◽  
pp. 281-284 ◽  
Author(s):  
Lucia Raimondo ◽  
Chiara Alessandra Cella ◽  
Roberto Moretto ◽  
Elide Matano ◽  
Chiara Carlomagno
Keyword(s):  
Case Report ◽  
Solid Tumors ◽  
Review Of The Literature ◽  
Digital Ischemia

Case reports Digital ischemia and occult malignancy

1996 ◽  
Vol 11 (4) ◽  
pp. 196-197 ◽  
Author(s):  
P. Paw ◽  
S. M. Dharan ◽  
J. M. Sackier
Keyword(s):  
Case Reports ◽  
Digital Ischemia ◽  
Occult Malignancy

Abstract 19443: Riociguat for the Treatment of Raynaud’s Phenomenon: A Single-dose, Double-blind, Randomised, Placebo-controlled Cross-over Study (DIGIT)

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Michael Huntgeburth ◽  
Johannes Kieβling ◽  
Gerrit Weimann ◽  
Verena Kiepsel ◽  
Soundos Saleh ◽  
...  
Keyword(s):  
Soluble Guanylate Cyclase ◽  
Cold Water ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Laser Speckle ◽  
Drug Intake ◽  
Symptom Duration ◽  
Small Pilot Study ◽  
Study Drug Administration ◽  
Digital Ischemia

Background: Raynaud’s phenomenon (RP) is a digital ischemia caused by vasoconstriction in the digital blood vessels. Triggers of RP include cold and stress. Medical therapy for RP is unsatisfactory, with many patients not responding to treatment. Here we investigated the safety, efficacy and pharmacokinetics of riociguat, a soluble guanylate cyclase stimulator, in patients with RP. Methods: Patients who had primary RP or secondary RP associated with systemic sclerosis (SSc), and a symptom duration of ≥1 year, were randomized to receive a single oral dose of riociguat 2 mg or placebo. Digital blood flow (DBF) in the right index finger was determined by Laser Speckle Contrast Analysis at room temperature (RT) and after 5 minutes of cold water exposure (CWE), both at baseline and 2 hours after study drug administration. Results: In the patients valid for evaluation (n=20), treatment with riociguat led to an increase in DBF versus baseline of 40.6% at RT and 15.1% after CWE. Based on predefined criteria, patients were considered responders if the placebo-corrected DBF after CWE increased by ≥10% versus baseline at 2 hours after drug intake. This was the case in 12/20 (60%) patients. The highest response rates were seen in patients with primary RP and limited cutaneous SSc, whereas patients with RP associated with diffuse cutaneous SSc responded less well. In responders, riociguat led to an increase in DBF versus baseline of 135.7% at RT and 38.9% after CWE. Riociguat Cmax (SD) 2 hours after drug intake was 76 (1.5) μg/ml, which is in the range previously seen in healthy volunteers and patients with pulmonary hypertension. Comparable Cmax values were observed in responders (81 [1.5] μg/ml) and non-responders (71 [1.6] μg/ml). AEs were reported in 5 patients receiving riociguat (headache, n=4; dyspepsia, n=1) and 1 patient receiving placebo (malaise). No serious AEs were reported. Conclusions: In this small pilot study, riociguat was well tolerated in patients with primary and secondary RP, and improved DBF versus placebo in 60% of patients after cold exposure.

Digital Ischemia in Systemic Sclerosis

2013 ◽  
pp. 30-31
Author(s):  
Peter C. Grayson ◽  
Peter A. Merkel
Keyword(s):  
Systemic Sclerosis ◽  
Digital Ischemia

Digital Ischemia Induced by Fesoterodine

2018 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Cyril Cosse ◽  
Benjamin Chaigne ◽  
Siguine Plaisant ◽  
Laurent Chouchana ◽  
Luc Mouthon
Keyword(s):  
Digital Ischemia
Sign in / Sign up

Export Citation Format

Share Document